Ex Parte BUECHLER et al - Page 9



              Appeal No. 2003-2084                                                                Page 9                
              Application No. 08/241,061                                                                                

                     3.  A method for identifying a crosstalk inhibitor for a ligand analogue conjugate,                
              wherein said ligand analogue conjugate comprises a binding site attached via a linkage                    
              site to a protein, polypeptide or label, and wherein said crosstalk inhibitor competes with               
              said linkage site for binding to a ligand receptor, wherein said ligand receptor is an                    
              antibody which binds said linkage site, said method comprising the steps of:                              
                     (a)  making a potential crosstalk inhibitor comprising at least one analogue of a                  
              linkage site of a ligand analogue conjugate,                                                              
                     (b)  testing said potential crosstalk inhibitor by:                                                
                            (i)  performing a first assay utilizing a first reaction mixture comprising said            
                            ligand analogue conjugate and a ligand receptor, wherein said ligand                        
                            receptor binds said linkage site causing a false positive result;                           
                            (ii)  performing a second assay utilizing a second reaction mixture                         
                            comprising said ligand analogue conjugate, said potential crosstalk                         
                            inhibitor and said ligand receptor;                                                         
                            (iii)  comparing the results of said first assay and said second assay, so                  
                            that no false positive result or a reduced false positive result in said                    
                            second assay indicates that said potential crosstalk inhibitor is useful                    
                            crosstalk inhibitor.                                                                        
                     As seen from claim 3 of the '524 patent, the USPTO has already determined that                     
              a method for identifying crosstalk inhibitors of the present invention is patentable                      
              subject matter.  The present enablement rejection questions whether one skilled in the                    
              art would be able to identify crosstalk inhibitors without undue experimentation.  It                     
              appears that the USPTO has already answered that question in the affirmative by                           
              issuing claim 3 of the '524 patent.                                                                       
                     Furthermore, the examiner's analysis does not take into account the starting                       
              point of a crosstalk inhibitor, i.e., knowledge of the linkage site which is part of the                  
              ligand analogue conjugate.  Development of a crosstalk inhibitor of the present                           
              invention does not begin in a vacuum.  Rather, the skilled artisan must start with                        






Page:  Previous  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  Next 

Last modified: November 3, 2007